Advertisement

Topics

Kensey Nash Company Profile

04:05 EDT 17th October 2017 | BioPortfolio

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occluded arteries.
The company was co-founded by Dr. Geoffrey Hartzler, pioneer of multi-vessel percutaneous transluminal coronary intervention (PTCI) and a recognized leader in the area of interventional cardiology. Incorporated in October 1997, the company is located in Carlsbad, California.

Location

735 Pennsylvania Drive
Exton
Pennsylvania
19341
United States of America

Contact

Phone: (484) 713-2100
Fax: (484) 713-2900
Email: Safecrossquestions@kenseynash.com


News Articles [110 Associated News Articles listed on BioPortfolio]

GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 juin 2018

GENFIT — Thursday, July 13th 2017 at 5:19pm UTC GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 ju...

Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic...

GENFIT ??? The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date!

  Life Sciences Jobs   ...

Nonalcoholic Steatohepatitis NASH Market Insights, Epidemiology and Market Forecast 2027 [Report Updated: 10072017] Prices from USD $5750

"DelveInsight's Nonalcoholic Steatohepatitis NASH Market Insights, Epidemiology and Market Forecast 2027 Reports provides an overview of the disease and global market size of the NASH for the 7MM Un...

Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment ...

Compelling unmet need for NAFLD/NASH drug to address estimated $35 billion treatment market by 2025 Read more...

Noninvasive test for NASH, fibrosis in patients with psoriasis

(HealthDay)—For patients with psoriasis receiving long-term methotrexate sodium therapy, a noninvasive test for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis (NASH FibroSure) can be used ...

Demand for liver transplant for NASH set to continue rising

(HealthDay)—Given population obesity trends, the increase in the demand for liver transplantation (LT) for nonalcoholic steatohepatitis (NASH) noted since 2000 is expected to continue, according to ...

GENFIT franchit une étape décisive pour le développement d’un test de diagnostic in-vitro (IVD) non-invasif dans la NASH

GENFIT — Friday, June 23rd 2017 at 6:30am UTC GENFIT franchit une étape décisive pour le développement d’un test de diagnostic in-vitro (IVD) non-invasif dans la NASH Achèvement de la...

PubMed Articles [105 Associated PubMed Articles listed on BioPortfolio]

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-re...

A Novel Role of Astrocyte Elevated Gene-1 (AEG-1) in Regulating Non-alcoholic Steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established mandating more in-depth inv...

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic steatosi...

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (kno...

Clinical Trials [113 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [22 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "Kensey Nash" on BioPortfolio

We have published hundreds of Kensey Nash news stories on BioPortfolio along with dozens of Kensey Nash Clinical Trials and PubMed Articles about Kensey Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Companies in our database. You can also find out about relevant Kensey Nash Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record